Published in J Neuroimmunol on May 15, 2009
Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology (2012) 1.24
The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation (2011) 1.19
Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity. J Affect Disord (2011) 0.98
PPAR agonists as therapeutics for CNS trauma and neurological diseases. ASN Neuro (2013) 0.82
PPARγ agonists improve survival and neurocognitive outcomes in experimental cerebral malaria and induce neuroprotective pathways in human malaria. PLoS Pathog (2014) 0.82
Regulation of Immune Responses and Autoimmune Encephalomyelitis by PPARs. PPAR Res (2010) 0.80
The Case for the Use of PPARγ Agonists as an Adjunctive Therapy for Cerebral Malaria. PPAR Res (2011) 0.78
Regulation of oligodendrocyte progenitor cell maturation by PPARδ: effects on bone morphogenetic proteins. ASN Neuro (2010) 0.78
Pioglitazone regulates myelin phagocytosis and multiple sclerosis monocytes. Ann Clin Transl Neurol (2015) 0.76
Promoting return of function in multiple sclerosis: An integrated approach. Mult Scler Relat Disord (2013) 0.76
The antidepressant-like effects of pioglitazone in a chronic mild stress mouse model are associated with PPARγ-mediated alteration of microglial activation phenotypes. J Neuroinflammation (2016) 0.76
Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis. PPAR Res (2016) 0.75
Pioglitazone, a PPARγ agonist rescues depression associated with obesity using chronic unpredictable mild stress model in experimental mice. Neurobiol Stress (2016) 0.75
Development of a high throughput drug screening assay to identify compounds that protect oligodendrocyte viability and differentiation under inflammatory conditions. BMC Res Notes (2016) 0.75
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord (2004) 4.83
Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. Reg Anesth Pain Med (2003) 3.87
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Lipid emulsion is superior to vasopressin in a rodent model of resuscitation from toxin-induced cardiac arrest. Crit Care Med (2009) 3.56
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet (2013) 2.89
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol (2009) 2.82
White matter changes in mild cognitive impairment and AD: A diffusion tensor imaging study. Neurobiol Aging (2005) 2.79
Lipid infusion accelerates removal of bupivacaine and recovery from bupivacaine toxicity in the isolated rat heart. Reg Anesth Pain Med (2006) 2.74
Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2007) 2.62
Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol (2009) 2.48
Underconnected, but how? A survey of functional connectivity MRI studies in autism spectrum disorders. Cereb Cortex (2011) 2.46
Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 2.28
Epinephrine impairs lipid resuscitation from bupivacaine overdose: a threshold effect. Anesthesiology (2009) 2.11
Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device. Mov Disord (2009) 2.00
Rating scales for dystonia: a multicenter assessment. Mov Disord (2003) 1.77
Predicting functional gains in a stroke trial. Stroke (2007) 1.76
Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord (2008) 1.71
A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol (2010) 1.70
Hippocampal disconnection contributes to memory dysfunction in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.63
Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem (2007) 1.61
Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci (2010) 1.59
Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology (2010) 1.53
Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain (2011) 1.50
Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease. J Neurosci (2002) 1.46
Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord (2005) 1.41
Health-related quality-of-life scales in Parkinson's disease: critique and recommendations. Mov Disord (2011) 1.31
Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis. J Neuroimmunol (2005) 1.29
Resuscitation with lipid versus epinephrine in a rat model of bupivacaine overdose. Anesthesiology (2008) 1.28
The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord (2008) 1.27
Anxiety rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 1.24
Impaired thalamocortical connectivity in autism spectrum disorder: a study of functional and anatomical connectivity. Brain (2013) 1.23
Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. J Neurosci (2009) 1.22
Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol (2012) 1.20
A novel fluorescent probe that is brain permeable and selectively binds to myelin. J Histochem Cytochem (2006) 1.19
The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro (2011) 1.19
Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem (2002) 1.18
Dystonia rating scales: critique and recommendations. Mov Disord (2013) 1.17
Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. Mol Pharmacol (2006) 1.14
Freedom from disease activity in multiple sclerosis. Neurology (2010) 1.14
P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis. J Neuroinflammation (2008) 1.12
Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol Aging (2006) 1.11
The clinical course of experimental autoimmune encephalomyelitis is associated with a profound and sustained transcriptional activation of the genes encoding toll-like receptor 2 and CD14 in the mouse CNS. Brain Pathol (2002) 1.10
Identification of complement 5a-like receptor (C5L2) from astrocytes: characterization of anti-inflammatory properties. J Neurochem (2005) 1.10
Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord (2010) 1.10
Atypical cortical connectivity and visuospatial cognitive impairments are related in children with chromosome 22q11.2 deletion syndrome. Behav Brain Funct (2008) 1.09
Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores. Mov Disord (2012) 1.07
Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. Mov Disord (2013) 1.07
Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. Neurol Sci (2012) 1.06
Longitudinal changes in white matter following ischemic stroke: a three-year follow-up study. Neurobiol Aging (2005) 1.06
The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes. J Neuroinflammation (2011) 1.05
Task force report: scales for screening and evaluating tremor: critique and recommendations. Mov Disord (2013) 1.05
The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis. J Neurochem (2006) 1.04
Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. J Leukoc Biol (2003) 1.04
Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1beta production. J Neuroinflammation (2004) 1.03
The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease. Neurobiol Aging (2011) 1.03
mTOR kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis. Glia (2012) 1.02
Determinants of quality of life in children with Gilles de la Tourette syndrome. Mov Disord (2009) 1.01
Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests? Mov Disord (2014) 1.01
Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood (2006) 1.00
Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J Neuroinflammation (2004) 1.00
A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res (2009) 0.99
Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. Parkinsonism Relat Disord (2013) 0.99
Neuroprotective actions of noradrenaline: effects on glutathione synthesis and activation of peroxisome proliferator activated receptor delta. J Neurochem (2007) 0.98
Assuring interrater reliability for the UPDRS motor section: utility of the UPDRS teaching tape. Mov Disord (2004) 0.97
Which dyskinesia scale best detects treatment response? Mov Disord (2013) 0.97
Teaching program for the Unified Dyskinesia Rating Scale. Mov Disord (2009) 0.96
Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain (2014) 0.95
Effect of pioglitazone treatment on behavioral symptoms in autistic children. J Neuroinflammation (2007) 0.95
Norepinephrine protects cortical neurons against microglial-induced cell death. J Neurosci Res (2005) 0.94
Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS). Mov Disord (2010) 0.93
Increasing CNS noradrenaline reduces EAE severity. J Neuroimmune Pharmacol (2009) 0.93
The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol (2006) 0.92
The role of the glia limitans in ADP-induced pial arteriolar relaxation in intact and ovariectomized female rats. Am J Physiol Heart Circ Physiol (2004) 0.92
Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain. Neurochem Res (2004) 0.92
Epinephrine induces rapid deterioration in pulmonary oxygen exchange in intact, anesthetized rats: a flow and pulmonary capillary pressure-dependent phenomenon. Anesthesiology (2012) 0.91
Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Mov Disord (2010) 0.91
Statin-associated exacerbation of myasthenia gravis. Neurology (2004) 0.91
Modulation of inducible nitric oxide synthase expression by sumoylation. J Neuroinflammation (2009) 0.91
Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation--critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. Mov Disord (2009) 0.90
Noradrenergic depletion increases inflammatory responses in brain: effects on IkappaB and HSP70 expression. J Neurochem (2003) 0.90
The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. Parkinsonism Relat Disord (2013) 0.90
fMRI activation changes during successful episodic memory encoding and recognition in amnestic mild cognitive impairment relative to cognitively healthy older adults. Dement Geriatr Cogn Disord (2008) 0.89
Atrophy and dysfunction of parahippocampal white matter in mild Alzheimer's disease. Neurobiol Aging (2010) 0.89
Estrogen inhibits NF kappa B-dependent inflammation in brain endothelium without interfering with I kappa B degradation. Neuroreport (2002) 0.89
The tools of the trade: a state of the art "How to Assess Cognition" in the patient with Parkinson's disease. Mov Disord (2014) 0.89
Intrinsic regulation of brain inflammatory responses. Cell Mol Neurobiol (2003) 0.88
Temporal stability of the Unified Dyskinesia Rating Scale. Mov Disord (2011) 0.88
Cognitive profile of LRRK2-related Parkinson's disease. Mov Disord (2015) 0.87
Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576. Neuropharmacology (2005) 0.86
The changing face of multiple sclerosis clinical trial populations. Curr Med Res Opin (2011) 0.86
Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years. Mov Disord (2011) 0.86
Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. Mov Disord (2012) 0.86
15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) and ciglitazone modulate Staphylococcus aureus-dependent astrocyte activation primarily through a PPAR-gamma-independent pathway. J Neurochem (2006) 0.86
Norepinephrine increases I kappa B alpha expression in astrocytes. J Biol Chem (2002) 0.85